Swansea University
Prifysgol Abertawe

Cronfa
Setting Research Free

Cronfa - Swansea University Open Access Repository

_____

This is an author produced version of a paper published in :
The Journal of Lipid Research

_____

Cronfa URL for this paper:

http://cronfa.swan.ac.uk/Record/cronfa26641

_____

Paper:

Connolly, K., Willis, G., Datta, D., Ellins, E., Ladell, K., Price, D., Guschina, I., Rees, D. & James, P. (2014).
Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia. *The Journal of Lipid Research, 55*(10), 2064-2072.

http://dx.doi.org/10.1194/jlr.M049726

_____

Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia

Katherine D Connolly[a]*, Gareth R Willis[a]*, Dev N Datta[b], Elizabeth A Ellins[a,c], Kristin Ladell[d], David A Price[d], Irina A Guschina[e], D Aled Rees[a] and Philip E James[a]

[a] Institute of Molecular and Experimental Medicine, School of Medicine, Cardiff University, Cardiff, CF14 4XN, United Kingdom

[b] Lipid Unit, Llandough Hospital, Cardiff, CF64 2XX, United Kingdom

[c] Institute of Life Sciences, College of Medicine, Swansea University, Singleton Park, Swansea, SA2 8PP, United Kingdom

[d] Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, CF14 4XN, United Kingdom

[e] School of Biosciences, Cardiff University, Museum Avenue, Cardiff, CF10 3AX, United Kingdom

Correspondence to Philip E. James, PhD, Institute of Molecular and Experimental Medicine, School of Medicine, Cardiff University, Cardiff, CF14 4XN, United Kingdom. Tel.: +44 29 20743512; fax: +44 29 20743500 jamespp@cardiff.ac.uk

*Both authors contributed equally

Word count: 4258

Abbreviated title: Apheresis reduces circulating microparticles

Abbreviations

DALI® - polyacrylate whole blood adsorption; FAME – fatty acid methyl ester; FH – familial hypercholesterolemia; GC-FID – gas chromatography with flame ionization detection; hsCRP – high sensitivity C-reactive protein; MP – microparticle; NTA – nanoparticle tracking analysis; PDSA – plasma dextran sulphate adsorption; PS – phosphatidylserine; TC – total serum cholesterol ; TF – tissue factor; TRPS – tuneable resistive pulse sensing; WBDSA – whole blood dextran sulphate adsorption

Abstract

Lipoprotein-apheresis (apheresis) removes LDL-cholesterol in patients with severe dyslipidemia. However, reduction is transient indicating the long-term cardiovascular benefits of apheresis may not solely be due to LDL removal. Microparticles (MPs) are submicron vesicles released from the plasma membrane of cells. MPs, particularly platelet-derived MPs, are increasingly being linked to the pathogenesis of many diseases. We aimed to characterize the effect of apheresis on MP size, concentration, cellular origin and fatty acid concentration in individuals with familial hypercholesterolemia (FH). Plasma and MP samples were collected from twelve individuals with FH undergoing routine apheresis. Tunable resistive pulse sensing (TRPS - np200) and nanoparticle tracking analysis (NTA) measured a fall in MP concentration (33% and 15% respectively, $p<0.05$) pre to post-apheresis. Flow cytometry showed MPs were predominantly Annexin V positive and of platelet (CD41) origin both pre- (88.9%) and post- (88.4%) apheresis. Fatty acid composition of MPs differed to that of plasma, though apheresis affected a similar profile of fatty acids in both compartments as measured by gas chromatography-flame ionization detection (GC-FID). MP concentration was also shown to positively correlate with thrombin generation potential. In conclusion, we show apheresis non-selectively removes Annexin V positive platelet-derived MPs in individuals with FH. These MPs are potent inducers of coagulation and are elevated in cardiovascular disease; this reduction in pathological MPs could relate to the long-term benefits of apheresis.

Supplementary key words

Introduction

Familial hypercholesterolaemia (FH) is a common genetic disorder that causes elevated levels of atherogenic lipoproteins in the plasma, particularly low-density lipoprotein cholesterol (LDL). Over 85% of FH cases are caused by mutations in the LDL receptor rendering these receptors unable to bind or internalise LDL and leading to accumulation in the plasma[1]. The disease follows an autosomal dominant pattern of inheritance and can result in heterozygote, or more serious homozygote forms[2]. In severe forms of FH, diet alteration and lipid lowering medications are often insufficient to lower LDL levels enough to abate atherosclerotic plaque formation[3]. These patients therefore require frequent (bi-weekly) lipoprotein-apheresis (hereafter referred to as "apheresis") treatments in combination with dietary and pharmacological intervention to control LDL levels[4].

Apheresis is a safe, well established procedure for the extracorporeal removal of LDL. Blood is removed from one arm and passed through a column to remove atherogenic lipoproteins before being returned to the body via the other arm. Different apheresis techniques may be utilised, but all reduce LDL by approximately 70% immediately following treatment [5–9]. However, post-treatment LDL levels are not maintained with levels rising to 50% of pre-treatment values within 2-4 days[10]. Despite this transiency, apheresis is associated with superior long-term cardiovascular benefits compared with alternative therapies[11–15].

Microparticles (MPs) are heterogeneous submicron vesicles released from many different cell types. Several terms exist to describe these vesicles, though here we use "MPs" as an umbrella term to encompass vesicles ranging from 30 nm – 1 μm in diameter. This range includes both exosomes and microvesicles. Exosomes are classically 30 – 100 nm in size and are produced from intracellular processing of endocytosed material which is then incorporated into exosomes and released from the cell by exocytosis. Microvesicles are vesicles ranging from 100 nm - 1μm released directly from the plasma membrane of cells in response to cellular activation or apoptosis. The phospholipid asymmetry of the cells' plasma membrane is disrupted and consequently phosphatidylserine (PS) is externalised to the outer membrane. This is commonly used to identify microvesicle populations via Annexin V binding. MPs are released both *in vivo* and *in vitro* into the external environment of many cell types, allowing subsequent isolation from biological fluids or conditioned culture media[16].

Increased numbers of MPs, particularly those derived from platelets, have been reported in many cardiovascular diseases (CVD)[17,18] though their function in both health and disease remains poorly understood. The surface of platelet MPs is reportedly up to 100-fold more procoagulant than that of activated platelets due to an increased density of PS, P-selectin and factor X[19]. Furthermore, MPs are known to carry specific mRNAs, microRNAs (miRs), proteins and lipid signalling molecules. These bioactive entities are thought to be delivered to target cells though the mechanism by which this interaction occurs is still unknown[20]. To date, little is known about the lipid concentration and profile

of MPs, though platelet MPs have been shown to transfer proinflammatory lipids to platelets leading to activation[20].

Heterozygous FH patients have previously been shown to have increased circulating levels of endothelial- and leukocyte-derived MPs compared to non-FH hypercholesterolaemia patients[21]. However, quantification of MPs in this study was achieved using flow cytometry which is not considered optimal due to the techniques' lack of sensitivity for particles <200 nm. To our knowledge, no data exists detailing the effects of apheresis on MPs in individuals with FH, though other extracorporeal methods have been previously shown to remove MPs[22,23].

Here we aimed to characterise size, concentration, cellular origin, fatty acids and thrombin generation of MPs in FH patients undergoing apheresis, hypothesizing that this treatment would reduce circulating MPs as well as LDL.

Methods

Patients

Twelve patients with clinically significant dyslipidaemia undergoing fortnightly apheresis consented to take part in the study. For clinical reasons patients underwent treatment using three different techniques: polyacrylate whole blood adsorption (DALI®; n=8), whole blood- (WB; n=1), or plasma- (P; n=3) dextran sulphate adsorption (DSA) as described previously[24]. Patients attended the Lipid Unit at University Hospital Llandough, Cardiff for apheresis treatment as part of their normal clinical care. Patients fasted for at least 4 hours prior to attendance and took their prescribed medication for at least 1 hour prior to the study, excluding vasoactive medications from which patients were asked to refrain. Routine anthropometric measurements were carried out prior to apheresis treatment. After 15 minutes of rest, vascular access was gained using 16 gauge 25 mm fistula needles into 2 anatomically distinct upper limb veins or by arterio-venous fistula. Blood samples were then drawn sequentially prior to and immediately after completion of apheresis, approximately 3 hours later. Seven healthy volunteers (free of CVD and medication) were also recruited to the study to compare MP concentration, size distribution, cellular origin and fatty acid profile with FH individuals. Ethical approval for obtaining blood samples was provided by the South East Wales Research Ethics Committee.

Biochemical Measurements

Blood samples were collected as described above into ethylenediaminetetraacetic acid (EDTA) and citrate vacutainers. An Aerostat automated analyser (Abbott Diagnostics, Berkshire, UK) was used to measure serum total cholesterol (TC), HDL and triglycerides; LDL was then estimated using the Friedwald equation. Glucose levels were determined by using the Aerostat chemistry system (Abbott Diagnostics, Berkshire, UK) and high sensitivity CRP (hsCRP) was measured using nephelometry (BN™ II system, Dade Behring, UK). Blood pressure (BP) measurements were taken with patients seated using the Vicorder system (Skidmore Medical, UK) as part of a separate study.

MP isolation

Blood, collected as above, was immediately centrifuged (1509 x g, 10 mins, 4°C) to obtain platelet-poor plasma (PPP). EDTA plasma was snap frozen in liquid nitrogen. Citrate plasma was ultracentrifuged (100,000 x g, 1 hour, 4°C) and the MP pellet was resuspended in either PBS and snap frozen in liquid nitrogen (for GC analysis), or in PBS containing 0.05% (v/v) Tween 20 (for MP size and concentration). The latter was then passed through a 1 μm filter (Supelco, Sigma Aldrich, UK)

and slow frozen overnight at -80°C in a Mr Frosty (Nalgene, Thermo Scientific, UK). Plasma and MPs were maintained at -80°C until analysis.

MP size and concentration

Two techniques were used to measure MP size and concentration: tunable resistive pulse sensing (TRPS) and nanoparticle tracking analysis (NTA). TRPS was carried out using the qNano (Izon Science, New Zealand) which uses an electrophoresis-based method to determine the size and concentration of MPs on a particle-by-particle basis. Particles pass through a tunable nanopore which detects particles within a specific size range. Therefore, in order to analyse MP size and concentration across a full spectrum, nanopores "100" and "200" (np100 and np200) were used. NTA was undertaken using the NanoSight LM10 (NanoSight Ltd, UK) with settings as previously described [25] using the NTA software (version 2.3). NTA uses the light scattering by MPs and tracks their Brownian motion in suspension over time to relate this to MP size and concentration. Sixty second videos were recorded in replicates of five per sample with camera sensitivity and detection threshold set to (14-16) and (5-6) respectively.

Microparticle origin

Flow cytometry was used to determine MP origin using a custom-built BD FACSAria II (BD Biosciences, CA). Forward and side scatter area (FSC-A and SSC-A respectively) were set to log scale and MPs were gated based on their FSC-A/SSC-A profile and in relation to platelets in fresh plasma. MP pellets were resuspended in 1x 0.22 µm-filtered Annexin V binding buffer (BD Biosciences, CA) and 100 µL of this was used for staining. MPs were stained in the dark (15 mins, RT) with Annexin V-FITC (1.57 µg/mL), CD41-PE-Cy5 (0.12 µg/mL), CD11b-PE-Cy7 (7.9 µg/mL), CD144-APC (4.1 µg/mL) and CD235a-PB (7.7 µg/mL) as markers of MPs, platelets, monocytes, endothelial cells and erythrocytes respectively (all antibodies from Biolegend, CA). Data were exported from the FACSDiva™ software (version 6) and subsequently analysed in FlowJo software (version 9.6.4; Tree Star Inc., OR).

MP fatty acid profile

Fatty acid profiles were analysed using gas chromatography with flame ionisation detection (GC-FID) as described previously[26]. Briefly, lipids were extracted from 200 µL of plasma or isolated MP samples (250 µL) with chloroform : methanol (1:2, v/v) by the method of Garbus et al[27]. Fatty acid

6

methyl esters (FAME) were prepared by incubation for 2 hours with 2.5% H_2SO_4 in dry methanol: toluene (2:1, v/v) at 70°C. A known amount of C19:0 (nonadecylic acid, Nu-Chek Prep. Inc., Elysian, MN, USA) was added as an internal standard, so that subsequent quantification of peaks (and, consequently, lipids) could be performed. FAME were analysed by gas chromatography (GC) using a Clarus 500 gas chromatograph (Perkin-Elmer 8500, Norwalk, CT), fitted with a 30 m × 0.25 mm i.d., 0.25 μm film thickness capillary column (Elite 225, Perkin-Elmer). The column temperature was held at 170°C for 3 minutes, then temperature-programmed to 220°C at 4°C/min. Nitrogen was the carrier gas at a flow rate 2 mL/min. FAME were identified routinely by comparing retention times of peaks with those of standard (Supelco 37 Component FAME Mix, Sigma Aldrich, UK, Nu-Chek Prep. Inc., USA). Perkin-Elmer Total Chrom Navigator software was used for data acquisition.

MP thrombin generation

To provide a working reservoir of plasma in which to test thrombin generation of MP, blood was drawn gently from healthy volunteers into a syringe containing 6 mM trisodium citrate (Sigma Aldrich, UK) and 20 μg/mL corn trypsin inhibitor (Cambridge BioScience, UK) and centrifuged (1024 x g, 10 minutes, 4°C) to yield "vehicle" PPP. Samples were then stored at -80°C until analysis.

To asses MP thrombin generation, calibrated automated thrombography (CAT) was used as described previously[28] with minor modifications. Samples were measured in duplicate using 96-well plates (round-bottomed, Immulon 2HB, Thermo Scientific, UK). Eighty μL of vehicle PPP (containing endogenous clotting factors) was added to each well with 20 μL of diluted (HEPES/NaCl buffer, pH 7.4) tissue factor solution to yield a final concentration of 1 pM (Innovin, Sysmex UK Ltd, UK). FH MP samples were assayed for thrombin generation both with and without exogenous tissue factor (TF) addition. Therefore, MPs (20 μL) were added to sample wells with the addition of either saline (20 μL, 0.9% NaCl) or TF (20 μL, 1pM final). Each sample was calibrated to a well containing 80 μL of PPP and 40 μL of thrombin calibrator (600 nM, Synapse BV, Netherlands). The plate was then warmed to 37°C for 5 minutes before addition of fluorogenic substrate (20 μL, Z-Gly-Gly-Arg-AMC, Bachem, UK). The fluorescent signal was then measured using a Fluoroskan Ascent plate reader (ThermoLabsystems, Finland) equipped with a 390/460 nm filter set (excitation/emission) at 15 s intervals until the thrombin generation reaction was complete. Data were analysed using Thrombinoscope™ software (Synapse BV, Netherlands) and correlated with MP concentration data.

Statistical Analysis

Data are presented as means ± SEM. A paired *t-test* (two-tailed) or a Wilcoxon matched pairs test was used for parametric and non-parametric data respectively. Analyses were conducted using GraphPad Prism (version 6; GraphPad Software Inc., CA) and a *p* value <0.05 was considered statistically significant.

Results

Anthropometric and biochemical data

Of the twelve participants in the study, 9 were male and 3 female with a mean age of 57.9 ± 10.3 years and a mean BMI of 30.0 ± 4.0 kg/m². Biochemical measurements are summarised in Table 1. Apheresis reduced TC, triglycerides, HDL, LDL hsCRP and systolic BP. No changes were observed in glucose levels, diastolic BP or heart rate.

MP size and concentration pre- versus post-apheresis

Two techniques, TRPS (using np100 and np200) and NTA were used to analyze MP size and concentration, therefore the detectability was compared for each technique pre- and post-apheresis (Supplementary Figure: SIA and B). The size distribution of MPs was similar for TRPS (np100 and np200) and NTA though the measured concentration varied greatly between the two techniques. Mode size of MPs did not change following apheresis by any technique (81.1 ± 19.6 to 78.4 ± 16.7, *p=0.3* for TRPS (np100), 170.3 ± 40.6 to 163.6 ± 29.2, *p=0.18* for TRPS (np200) and 93.3 ± 21 to 88.2 ± 14.7 nm, *p=0.32*: for NTA). TRPS (np100) measured no difference in concentration pre- to post-apheresis ($4.6 \times 10^{11} \pm 1.3 \times 10^{11}$ to $3.1 \times 10^{11} \pm 1.0 \times 10^{11}$: *p=0.18*; Figure 1A). However, TRPS (np200) and NTA both measured a decrease in MPs pre- vs post-apheresis ($4.7 \times 10^{10} \pm 8.8 \times 10^{9}$ to $3.1 \times 10^{10} \pm 5.6 \times 10^{9}$, and $1.9 \times 10^{12} \pm 2.4 \times 10^{11}$ to $1.5 \times 10^{12} \pm 2.4 \times 10^{11}$ particles/mL: *p=0.013* and *0.025*; Figure 1C and E for TRPS (np200) and NTA respectively). Total cholesterol was measured in the MP fraction and was below the detectability of the assay (<0.01 mmol/L). Size/concentration distributions of MPs are shown pre- to post-apheresis for each technique. TRPS (np100) and NTA show no preferential reduction according to MP size (Figure 1B and F respectively) whereas TRPS (np200) shows a reduction in MPs between 200-249 nm (Figure 1D, *p*=0.01). The type of apheresis received by patients was not shown to affect MP concentration (Supplemental Table SI); however the study was not powered to measure this as an endpoint. Comparison of MPs in FH with healthy volunteers showed a trend (non-significant) towards an increase in total concentration however, the size distribution showed individuals with FH had increased concentrations of MPs between 50-100 nm (*p*<0.05, Supplemental Figure SIIA/B respectively).

Effect of apheresis on MP origin

MPs falling within the MP gate (Figure 2A) showed no change in apportion of Annexin V positivity following apheresis (Figure 2B). Of these Annexin V positive MPs, there were also no changes in the

proportions derived from platelets (CD41), endothelial cells (CD144), monocytes (CD11b) or erythrocytes (CD235a), (Figure 2C). MPs positive for both Annexin V and CD41 accounted for the majority (~ 90%) of MPs measured. The same was also true for MPs in healthy volunteers, though there was a minor increase in the proportion of endothelial-derived MPs in individuals with FH compared to healthy volunteers (p=0.03, Supplementary Figure SIII). The apportion of MPs showed no observable differences depending on the type of apheresis (Supplemental data, Table SI), though the study was not powered on this basis.

MP fatty acid concentration and profile pre- versus post-apheresis

Little is known about the lipid concentration of MPs, thus we sought to determine the fatty acid concentration and profile of MPs compared with that of the corresponding plasma and to observe the effect of apheresis. Total plasma fatty acid concentration decreased following apheresis (8.1 ± 1.3 to 4.6 ± 0.8 mM; $p = 0.01$) though this was not mirrored in the MP fraction (Figure 3A and C respectively). Five individual fatty acids were altered in the plasma following apheresis ($p<0.05$): C14:0 (myristic acid); C18:0 (steric acid); C18:1n7 (cis-vaccenic acid); C20:5n3 (eicosapentaenoic acid) and C22:3n3 (docosatrienoic acid), the former three also being altered in the MP fraction ($p<0.05$, Figure 3B and D respectively). Interestingly, comparison of the compartments; plasma and MPs, revealed 10 fatty acids differed in composition ($p<0.05$). This was true in pre- and post-apheresis samples however the ten fatty acids were not the same. Comparing FH to healthy volunteers, both plasma and MP fatty acid concentration was elevated in individuals with FH (p=0.02 and p=0.01 Supplementary Figure SIVA and C respectively). Eight fatty acids were different in both plasma and MPs comparing healthy volunteers and individuals with FH ($p<0.05$, Supplementary Figure SIVB and D respectively), and apheresis had a similar effect on fatty acids in either compartment. This was consistent with all types of apheresis received (Supplemental data, Table SI).

MP thrombin generation

Thrombin generation of MPs was analysed pre- to post-apheresis and was also correlated with total MP concentrations. No change was observed in MP peak thrombin generation pre- to post-apheresis (14.8 ± 2.9 to 16.6 ± 4.1 nM, $p = 0.6$). However, MP thrombin generation over time (area under the curve, AUC) was positively correlated with MP concentration measured by TRPS (np100) and NTA (r = 0.626, $p = 0.001$ and r = 0.424, $p = 0.04$ respectively). Thrombin AUC showed no correlation with MP concentration measured by TRPS (np200). Furthermore, when tissue factor was added to

MPs (to exogenously initiate maximum thrombin generation), thrombin AUC no longer correlated with MP concentration.

Discussion

Circulating MPs are reportedly elevated in a number of diseases including in patients with severe hypercholesterolemia[21,29]. The present study shows novel data regarding the effects of apheresis on MP size, concentration, origin, fatty acid concentration and thrombin generation in patients with FH. Our data demonstrate that apheresis reduces circulating MP concentration, the majority of which are Annexin V positive MPs derived from platelets.

Several methods exist to measure MPs, though often the technique employed is heavily dictated by the research question and protocol, and each exhibits unique advantages/limitations. Thus we sought to employ two well-established methods for MP measurement in order to capture the full spectrum of MP sizes. To our knowledge, TRPS and NTA have not previously been subjected to a direct comparison in biological samples. Our data illustrate that the range of detectability of TRPS (np100 and np200) and NTA are similar, and although they differ vastly in reported MP concentration reported, taken together there is considerable agreement.

No change was observed with TRPS or NTA in mode particle size pre- versus post-apheresis. TRPS using the np200 and NTA showed a fall in MP concentration pre- versus post-apheresis. MPs within the range of 200-250 nm were reduced the most pre- versus post-apheresis which is much greater than the size of LDL particles[30], indicating the techniques are measuring a reduction MPs and not LDL. MP concentration did not fall when measured with TRPS using the np100. This further supports that the observed fall in MP concentration by the np200 and NTA was not due to either technique detecting LDL, as the particulate size of LDL lies within the sensitivity of the np100 pore range. MPs were also shown to be elevated in the exosomal range in individuals with FH compared to healthy volunteers. Total MP concentration also appears elevated in individuals with FH though this did not quite reach significance.

Flow cytometric measurement of MPs revealed no changes in Annexin V positivity or cellular origin following apheresis. In keeping with previous data [21,31,32] platelet-MP occupied the majority of the MP population (88.9 ± 13%). Taken together with the fall in MP concentration this would suggest that apheresis non-selectively removes MPs, the majority of which are Annexin V positive and derived from platelets. These MPs have not only been shown to be elevated in a variety of disease states[33–38] but also to promote coagulation[19], atherosclerotic plaque formation[39] and to be associated with atherothrombotic events[35]. Non-selective removal of these MPs by apheresis may reduce the risk of thrombus formation by slowing the progression of atherosclerotic lesions thereby complementing the effect of LDL removal. MPs in healthy volunteers were also found to be mainly Annexin V positive and of platelet origin. It would appear that individuals with FH have a greater number of these circulating Annexin V/platelet positive MPs. Individuals with FH had a greater apportion of

endothelial-derived MPs, perhaps suggesting a greater level of endothelial activation compared to healthy volunteers, although the percentage of the total was still low (<2%).

GC-FID was used to measure fatty acid concentration and composition in plasma and MPs. The relative atheroprotective mechanisms of unsaturated and polyunsaturated fatty acids are well documented[40] as are the data implicating saturated fatty acids in arterial wall lipid accumulation and atherosclerotic plaque formation[41]. MPs have been shown to carry a specific cargo of proteins, genetic material and small molecules including fatty acids[42] that can initiate a pro-inflammatory response in target cells[20]. Here, total fatty acid concentration of plasma was decreased following apheresis, however MP fatty acid levels did not change following apheresis. Thus, although the overall number of MPs decreases pre- versus post-apheresis, the fatty acid concentration per MP remains the same. Interestingly, apheresis seemed to affect individual fatty acids differently in plasma compared with the MP fraction; however the physiological relevance of this remains to be elucidated. Furthermore, when plasma was directly compared with the MP fraction, the apportion of fatty acids were found to be different between compartments. This suggests that the fatty acid composition of MPs is independent to that of surrounding plasma, a concept we have previously found in a separate cohort of patients with polycystic ovary syndrome (unpublished data). Several fatty acids were different in individuals with FH compared to healthy volunteers in both plasma and MPs, however affected fatty acids and the trends (i.e. increase or decrease) were the same. Similarly to the findings in FH, in healthy volunteers the fatty acid composition of MPs did not reflect that of plasma.

The potential of MPs to generate thrombin was assessed using CAT. No change was observed in MP peak thrombin generation pre- versus post-apheresis. However, total MP concentration measured by either TRPS (np100) or NTA showed a positive correlation with the total thrombin AUC whereas MP concentration measured by TRPS (np200) showed no correlation. Taken together, this suggests a reduction in MPs is associated with decreased thrombin generation capacity and that smaller MPs, particularly exosomes, are associated with an increased total thrombin generation over time. We conclude this on the basis that both TRPS (np100) and NTA have an increased sensitivity for MPs in the exosomal range compared to TRPS (np200) (Supplemental Figure SI). Furthermore, individuals with FH were shown to have an increased circulating population of smaller MPs compared with healthy individuals (Supplemental Figure SII). Both TRPS (np100) and NTA showed a trend towards reduction in exosomal populations of MPs following apheresis (Figure 1B/F respectively), though this did not reach significance. This could suggest that the increased circulating population of exosomes in individuals with FH makes their MP fraction more procoagulant. Apheresis treatment non-selectively removes MPs and could potentially reduce the procoagulant potential of exosomes and smaller MPs. Our results confirm MPs have endogenous TF activity and can stimulate thrombin generation, a finding in keeping with previous research[43,44]. When exogenous TF was added to MPs to stimulate

thrombin generation, the correlation between MP concentration and AUC was lost reflecting maximum thrombin generation.

Patients in this study received apheresis based on individual clinical requirements resulting in the use of 3 different types of apheresis treatment. Though there was no observable difference between apheresis technique and MP concentration (Supplemental Table SI), the current study was not designed to assess this. *In vitro* studies have shown the surface morphology of the adsorbent polymer may affect MP production[45], though this requires confirmation *in vivo*. FH patients were studied as part of their routine clinical outpatient treatment. Clearly, having now established apheresis directly influences MP concentration, longitudinal studies will help to establish whether the reduction in atherogenic MPs is maintained whilst further exploring the physiological relevance this reduction in MPs has in regards to CVD pathology. The thrombin generation of patient MP samples was measured in the presence of pooled, healthy plasma to specifically test the activity of MPs as opposed whole patient plasma (that would likely reflect the total influence of apheresis). Future studies should assess the procoagulant activity of plasma pre- to post-apheresis to confirm this reduction in atherogenic MPs. Finally, Annexin V binding was used to classify MP populations for identification of cellular origin using flow cytometry. It is acknowledged that many flow cytometers have a practical lower limit of around 200 nm. Therefore smaller MPs, particularly exosomes are below the detectability of these machines, and the fluorescence data obtained from a given sample does not completely reflect the full range of MP sizes observed by NTA and TRPS Despite this, flow cytometry is the most reliable technique to assess surface antigen expression of MPs. Importantly, NTA and TRPS confirm MPs within the range of 200-250 nm were reduced the most pre- versus post-apheresis and are likely reflected by the flow cytometric results. The use of Annexin V positivity to identify MP populations is used widely [31,46,47] but has recently been questioned[48]. As the majority (~90%) of MPs here were Annexin V positive, we chose to accept this as our MP population for subsequent staining. Our rationale was based on the fact that despite not all MPs binding Annexin V, only Annexin V positive MPs have been shown to possess procoagulant activity[48].

In summary, apheresis reduces the concentration of circulating MPs in patients with FH, the majority of which are Annexin V and platelet positive. Though MP concentration is reduced, apheresis has no effect on the total fatty acid concentration of MPs. Fatty acid composition of MPs is unique and does not reflect that of surrounding plasma. Each compartment is affected differently by apheresis though the clinical relevance of this requires further investigation. MP concentration (particularly in the exosomal range) was found to positively correlate with total thrombin generation, suggesting that a reduction in MP concentration via apheresis in FH may reduce the ability of MPs to produce thrombin. The removal of MPs that are predominantly Annexin V and platelet-derived is a novel finding, supporting the notion that apheresis may have beneficial cardiovascular effects beyond

lipoprotein removal. Future work should establish whether MP reduction during apheresis correlates with the longer-term benefits of this treatment.

Acknowledgements

Disclosures

None.

References

1. Goldstein JL, Brown MS. The LDL receptor locus and the genetics of familial hypercholesterolemia. *Annu Rev Genet*. 1979;13:259–89.

2. Brown M, Hobbs H, Goldstein JL. *The Online Metabolic and Molecular Bases of Inherited Disease*. 8th editio. New York: McGraw-Hill; 2001:2863–913.

3. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*. 2004;110(2):227–39.

4. Orsoni A, Villard EF, Bruckert E, et al. Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia. *J Lipid Res*. 2012;53(4):767–75.

5. Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. *Lancet*. 1981;2(8254):1005–7.

6. Yokoyama S, Hayashi R, Kikkawa T, et al. Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits. *Arteriosclerosis*. 4(3):276–82.

7. Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. *Klin Wochenschr*. 1987;65(4):161–8.

8. Agishi T, Kaneko I, Hasuo Y, et al. Double filtration plasmapheresis. 1980. *Ther Apher*. 2000;4(1):29–33.

9. Otto C, Kern P, Bambauer R, Kallert S, Schwandt P, Parhofer KG. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. *Artif Organs*. 2003;27(12):1116–22.

10. Kroon AA, van't Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. *Atherosclerosis*. 2000;152(2):519–26.

11. Kroon AA, Aengevaeren WR, van der Werf T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. *Circulation*. 1996;93(10):1826–35.

12. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. *Br Med J (Clin Res Ed)*. 1985;291(6510):1671–3.

13. Gordon BR, Kelsey SF, Dau PC, et al. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. *Am J Cardiol*. 1998;81(4):407–11.

14. Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. *Am J Cardiol*. 1998;82(12):1489–95.

15.	Seidel D. H.E.L.P. apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience. *Artif Organs*. 1996;20(4):303–10.

16.	Van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. *Pharmacol Rev*. 2012;64(3):676–705.

17.	Katopodis JN, Kolodny L, Jy W, et al. Platelet microparticles and calcium homeostasis in acute coronary ischemias. *Am J Hematol*. 1997;54(2):95–101.

18.	Nomura S, Komiyama Y, Kagawa H, Iwasaka T, Takahashi H, Fukuhara S. Microparticles and coronary artery disease. *Am J Hematol*. 1997;56(4):296.

19.	Sinauridze EI, Kireev DA, Popenko NY, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. *Thromb Haemost*. 2007;97(3):425–34.

20.	Barry OP, Kazanietz MG, Praticò D, FitzGerald GA. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway. *J Biol Chem*. 1999;274(11):7545–56.

21.	Suades R, Padró T, Alonso R, López-Miranda J, Mata P, Badimon L. Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in FH patients. *Thromb Haemost*. 2013;111(1).

22.	Abdelhafeez AH, Jeziorczak PM, Schaid TR, et al. Clinical CVVH model removes endothelium-derived microparticles from circulation. *J Extracell vesicles*. 2014;3.

23.	Umekita K, Hidaka T, Ueno S, et al. Leukocytapheresis (LCAP) decreases the level of platelet-derived microparticles (MPs) and increases the level of granulocytes-derived MPs: a possible connection with the effect of LCAP on rheumatoid arthritis. *Mod Rheumatol*. 2009;19(3):265–72.

24.	Lee WP, Datta BN, Ong BB, Rees A, Halcox J. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia. *Am J Cardiovasc Drugs*. 2011;11(6):363–70.

25.	Webber J, Clayton A. How pure are your vesicles? *J Extracell vesicles*. 2013;2: 19861.

26.	Garaiova I, Guschina IA, Plummer SF, Tang J, Wang D, Plummer NT. A randomised cross-over trial in healthy adults indicating improved absorption of omega-3 fatty acids by pre-emulsification. *Nutr J*. 2007;6:4.

27.	Garbus J, Deluca HF, Loomans ME, Strong FM. The rapid incorporation of phosphate into mitochondrial lipids. *J Biol Chem*. 1963;238:59–63.

28.	Collins PW, Macchiavello LI, Lewis SJ, et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. *Br J Haematol*. 2006;135(2):220–7.

29.	Georgescu A, Alexandru N, Andrei E, et al. Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan. *J Thromb Haemost*. 2012;10(4):680–91.

30.   Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. *J Lipid Res*. 1982;23(1):97–104.

31.   Christersson C, Johnell M, Siegbahn A. Evaluation of microparticles in whole blood by multicolour flow cytometry assay. *Scand J Clin Lab Invest*. 2013;73(3):229–39.

32.   Robert S, Poncelet P, Lacroix R, et al. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? *J Thromb Haemost*. 2009;7(1):190–7.

33.   Ichijo M, Ishibashi S, Ohkubo T, et al. Elevated Platelet Microparticle Levels after Acute Ischemic Stroke with Concurrent Idiopathic Thrombocytopenic Purpura. *J Stroke Cerebrovasc Dis*. 2013.

34.   Pereira J, Alfaro G, Goycoolea M, et al. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. *Thromb Haemost*. 2006;95(1):94–9.

35.   Namba M, Tanaka A, Shimada K, et al. Circulating platelet-derived microparticles are associated with atherothrombotic events: a marker for vulnerable blood. *Arterioscler Thromb Vasc Biol*. 2007;27(1):255–6.

36.   Nomura S, Suzuki M, Katsura K, et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. *Atherosclerosis*. 1995;116(2):235–40.

37.   Sabatier F, Darmon P, Hugel B, et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. *Diabetes*. 2002;51(9):2840–5.

38.   Tan KT, Tayebjee MH, Lim HS, Lip GYH. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. *Diabet Med*. 2005;22(12):1657–62.

39.   Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayashi J. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. *Atherosclerosis*. 2001;158(2):277–87.

40.   Hansen SN, Harris WS. New evidence for the cardiovascular benefits of long chain omega-3 fatty acids. *Curr Atheroscler Rep*. 2007;9(6):434–40.

41.   De Pascale C, Avella M, Perona JS, Ruiz-Gutierrez V, Wheeler-Jones CPD, Botham KM. Fatty acid composition of chylomicron remnant-like particles influences their uptake and induction of lipid accumulation in macrophages. *FEBS J*. 2006;273(24):5632–40.

42.   Deng Z-B, Zhuang X, Ju S, et al. Exosome-like nanoparticles from intestinal mucosal cells carry prostaglandin E2 and suppress activation of liver NKT cells. *J Immunol*. 2013;190(7):3579–89.

43.   Nielsen MH, Beck-Nielsen H, Andersen MN, Handberg A. A flow cytometric method for characterization of circulating cell-derived microparticles in plasma. *J Extracell vesicles*. 2014;3.

44.   Novelli F, Neri T, Tavanti L, et al. Procoagulant, tissue factor-bearing microparticles in bronchoalveolar lavage of interstitial lung disease patients: an observational study. *PLoS One*. 2014;9(4):e95013.

45.   Weiss R, Spittler A, Schmitz G, Fischer MB, Weber V. Thrombocyte Adhesion and Release of Extracellular Microvesicles Correlate with Surface Morphology of Adsorbent Polymers for Lipid Apheresis. *Biomacromolecules*. 2014.

46.   Larson MC, Woodliff JE, Hillery CA, Kearl TJ, Zhao M. Phosphatidylethanolamine is externalized at the surface of microparticles. *Biochim Biophys Acta*. 2012;1821(12):1501–7.

47.   Al Kaabi A, Traupe T, Stutz M, Buchs N, Heller M. Cause or effect of arteriogenesis: compositional alterations of microparticles from CAD patients undergoing external counterpulsation therapy. *PLoS One*. 2012;7(10):e46822.

48.   Connor DE, Exner T, Ma DDF, Joseph JE. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. *Thromb Haemost*. 2010;103(5):1044–52.

Table 1: Biochemical and physiological measurements pre- and post-apheresis. Data are presented as mean ± SEM or median (range). n=12. TC: total cholesterol, hsCRP: high sensitivity C-reactive protein, BP: blood pressure, bpm: beats per minute. * denotes statistical significance.

Table 2: Fatty acid composition of the plasma and MP fraction. Individual fatty acid composition of the plasma and MPs were directly compared in pre-apheresis and post-apheresis samples. Data are presented as mean ± SEM (n=12). * denotes statistical significance.

Figure 1: MP concentration and size distributions pre- and post-apheresis. MP size and concentration was measured in pre- and post-apheresis samples using TRPS (np100 and np200) and NTA. Mean concentration of MPs pre- and post-apheresis is shown for TRPS np100 (**A**), np200 (**C**) and NTA (**E**). Size/concentration distribution of MPs pre- and post-apheresis is shown for TRPS np100 (**B**), TRPS np200 (**D**) and NTA (**F**). Concentrations are given in particles/mL of plasma. Data are presented as mean ± SEM (n=12). $^*p<0.05$.

Figure 2: MP origin following apheresis. MPs from pre and post-apheresis samples were analyzed by flow cytometry to determine cellular origin. Forward and side scatter areas (FSC-A and SSC-A respectively) of platelets from fresh plasma were used to determine a submicron gate where only Annexin V positive MPs were analyzed. A representative dot blot of FSC-A vs. SSC-A indicates the position of the MP gate (**A**, kept consistent for all samples). Samples were stained with Annexin V (**B**), CD41, CD144, CD235a and CD11b to identify the proportion derived from platelets, endothelial cells, erythrocytes and monocytes respectively (**C**). Data are presented as mean ± SEM (n=12).

Figure 3: GC-FID analysis of MPs following apheresis. Total fatty acid concentration of plasma and MPs (**A** and **C** respectively) followed by fatty acid profiling to determine compositional changes pre- to post-apheresis (**B** and **D** respectively). Data are presented as mean ± SEM. (n=12) $^*p<0.05,$ $^{**}p<0.01$.

TABLE 1

	Pre-Apheresis	Post-Apheresis	% change	*p value*
TC (mmol/L)	6.1 ± 0.5	2.7 ± 0.2	- 57.1	*<0.0001**
HDL (mmol/L)	1.1 (0.4-2.3)	0.9 (0.2-2.1)	- 21.0	*0.003**
Triglycerides (mmol/L)	1.8 ± 0.2	0.9 ± 0.1	- 50.0	*<0.0001**
LDL (mmol/L)	4.1 ± 0.4	1.4 ± 0.2	- 66.1	*<0.0001**
TC/HDL	5.8 (3.3-10.0)	3.1 (1.9-8.2)	- 41.9	*0.0005**
Glucose (mmol/L)	5.7 ± 0.3	6.1 ± 0.3	8.4	*0.07*
hsCRP (mg/L)	0.8 (0.2-16.9)	0.6 (0.2-13.8)	- 29.8	*0.003**
Systolic BP (mmHg)	140 ± 5	148 ± 6	6.5	*0.02**
Diastolic BP (mmHg)	81.8 ± 2.8	82.8 ± 2.7	1.4	*0.45*
Heart rate (bpm)	55.8 ± 2.9	58.8 ± 3.4	5.8	*0.09*

TABLE 2

Fatty acid	PRE APHERESIS			POST-APHERESIS		
	Plasma composition (%)	MP composition (%)	*p* value	Plasma composition (%)	MP composition (%)	*p* value
C14:0	0.6 ± 0.1	1.09 ± 0.1	*0.04**	0.9 ± 0.1	0.6 ± 0.07	*0.008**
C14:1	0.04 ± 0.01	0.1 ± 0.02	*0.006**	0.06 ± 0.1	0.1 ± 0.08	*0.4*
C16:0	15.7 ± 3.2	27.3 ± 3.2	*0.07*	10.5 ± 3.9	25.1 ± 1.2	*0.002**
C16:1n7	2.5 ± 0.6	3.4 ± 0.4	*0.4*	2.0 ± 0.8	4.6 ± 0.7	*0.02**
C18:0	5.0 ± 0.8	8.2 ± 0.9	*0.07*	3.1 ± 1.3	10.6 ± 0.6	*<0.001**
C18:1n9	15.0 ± 4.2	6.2 ± 3.3	*0.04**	10.1 ± 6.0	17.7 ± 5.4	*0.4*
C18:1n7	11.3 ± 4.2	32.5 ± 3.4	*0.003**	31.8 ± 7.0	17.4 ± 5.4	*0.1*
C18:2n6	22.2 ± 5.8	13.3 ± 1.7	*0.03**	14.0 ± 3.6	15.3 ± 1.2	*0.7*
C20:1	0.4 ± 0.1	0.3 ± 0.03	*0.6*	0.4 ± 0.06	0.4 ± 0.07	*0.3*
C20:2n6	1.7 ± 1.0	0.6 ± 0.09	*0.2*	1.5 ± 0.1	0.8 ± 0.09	*<0.001**
C20:5n3	0.9 ± 0.2	0.7 ± 0.15	*0.03**	2.2 ± 0.4	0.9 ± 0.15	*0.002**
C22:0	0.3 ± 0.05	0.14 ± 0.06	*0.02**	0.5 ± 0.07	0.14 ± 0.04	*0.001**
C22:3n3	0.1 ± 0.03	0.15 ± 0.09	*0.7*	0.2 ± 0.04	0.02 ± 0.01	*<0.001**
C22:3n6	0.4 ± 0.1	0.2 ± 0.1	*0.09*	0.9 ± 0.4	0.03 ± 0.03	*0.004**
C22:5n3	0.2 ± 0.06	0.07 ± 0.04	*0.04**	0.2 ± 0.1	0.3 ± 0.3	*0.8*
C22:6n3	1.2 ± 0.2	1.1 ± 0.2	*0.09*	2.4 ± 0.6	1.2 ± 0.2	*0.09*
C24:0	0.07 ± 0.03	0.002 ± 0.002	*0.009**	0.2 ± 0.05	0.02 ± 0.02	*0.003**
C24:1n9	0.9 ± 0.2	0.2 ± 0.1	*0.006**	1.6 ± 0.7	0.04 ± 0.02	*0.08*

FIGURE 1

FIGURE 2

FIGURE 3